Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)

Part of paid clinical trials in Rosharon, Texas.

Sponsor
Ebima Clifford Okundaye
Study ID
NCT07161843
Phase
PHASE2/PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Acute Renal Failure (ARF)
  • Acute Tubular Necrosis

Eligibility Criteria

Sex
ALL
Age
10 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • QRX-3 — DRUG
    Combination of QRX-3 with standard therapy will be given to one arm in trial , another arm will receive placebo

Study Details

Use of QRX-3 in hospitalized patients with pediatric and adult patients with acute tubular necrosis renal failure

Key Dates

Start date
Jun 30, 2026
Status verified
Feb 2026
Primary completion
Dec 30, 2026
Completion
Feb 1, 2027

Study Design

Enrollment
500 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Use of QRX-3 in addition to standard therapy
    QRX-3 drug orally as twice daily in addition to standard conventional therapy will be given to this group for 28 days
  • Placebo Comparator: control group
    placebo twice daily will be given to this group in addition to standard therapy

Primary Outcome Measure

Rate of change in creatinine glomerular filtration rate [ Time Frame: 28 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Neukidney IncRosharonTexas77583-

Find similar trials in Rosharon, TX

By research site
Neukidney Inc· Rosharon, TX